Acceptability and the course of major depression under newer antidepressant treatment -One-year open-label, randomized, flexible dose study of either SSRI or SNRI in the treatment of major depression-

Trial Profile

Acceptability and the course of major depression under newer antidepressant treatment -One-year open-label, randomized, flexible dose study of either SSRI or SNRI in the treatment of major depression-

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Duloxetine (Primary) ; Escitalopram (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms ACCEPT
  • Most Recent Events

    • 16 Mar 2017 Planned number of patients changed from 242 to 160.
    • 16 Mar 2017 Planned End Date changed from 31 Dec 2016 to 31 Mar 2018.
    • 30 Sep 2014 Status changed from not yet recruiting to recruiting, as per University Hospital Medical Information Network - Japan record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top